An observational study in T1D, Type 1 Diabetes (T1D) and Type 1 Diabetes, sponsored by Adhera Health, Inc.. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Adhera Health, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.
Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 31st largest by enrollment of the 36 observational ones that give a count, is one of 18 that started in 2025, is one of 36 observational ones, and was the 138th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 18+
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18–65
Air Liquide Healthcare Spain · Sites in Spain
Ages 18+
Institut d'Investigacions Biomèdiques August Pi i Sunyer · Sites in Spain
Ages 18+ · Women only
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 18–45 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 43 · Phase 4 4
First in 2001; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 153 across the 113 interventional studies, 170 across the 36 observational. Of the 108 that completed or were terminated, 42 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 150 have an industry lead sponsor. The 10 most frequent:
Adhera Health, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Adhera Health, Inc. has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
10 of the studies in Diabetes Mellitus, Type 1 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT07290868Fundacion Miguel ServetDiactive-1: Scaled-up Personalized mHealth Program for Youth With Type 1 Diabetes | 2026-12 |
| NCT06450730Maimónides Biomedical Research Institute of CórdobaEffectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D). The main questions it aims to answer are:
Findings from this study will help determine whether the system can support future development of data-driven interventions for families managing pediatric T1D.
The study population consists of caregivers of children with type 1 diabetes recruited from Hospital Miguel Servet in Spain. Eligible caregivers are adults who serve as the primary caregiver for a child under 18 years old with a confirmed diagnosis of T1D and who uses the FreeStyle Libre 2 continuous glucose monitoring system. Families must be willing to share the child's CGM data and have experienced at least two severe glucose events in the previous month. Caregivers must own a compatible smartphone and be able to use a mobile sensing system. Exclusion criteria include significant cognitive or physical impairments, inability to read or understand Spanish, or participation in other clinical trials involving psychological or diabetes-related interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
This cohort includes caregivers of children with type 1 diabetes who will use the biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for 2 months. No interventions are administered; caregivers use the system as part of this observational feasibility study.
Other: Use of Biopsychosocial Sensing System
Participants use a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for a 2-month period. The system collects caregiver emotional well-being data through computer adaptive testing (CAT) and ecological momentary assessment (EMA), along with children's CGM data. This is an observational study and no treatment or behavioral intervention is administered.
Feasibility of the Biopsychosocial Sensing System
Feasibility will be assessed using metrics from the Adhera Caring Digital Program®, including: \- Response rate to Ecological Momentary Assessment (EMA) prompts
Time frame: From enrollment to the end of study at month 2
Feasibility of the Biopsychosocial Sensing System
Feasibility will be assessed using metrics from the Adhera Caring Digital Program®, including: \- Completion rates of scheduled CAT assessments
Time frame: From enrollment to the end of study at month 2
Usability and acceptability of the system
Outcome Measure: System Usability Scale (SUS) score. Unit of Measure: SUS score (0-100, higher scores indicate better usability). Description: The System Usability Scale is a 10-item scale based on a 5-point Likert scale assessing perceived usability.
Time frame: At the end of the study (Month 2)
Caregiver Distress Measured by Ecological Momentary Assessment (EMA)
Caregiver distress will be measured using Ecological Momentary Assessment (EMA) delivered via smartphone. Distress will be quantified using EMA distress scores reported in response to daily prompts. Unit of Measure: EMA distress score (continuous scale)
Time frame: From enrollment to the end of the study at month 2
Caregiver Distress Measured by Computer Adaptive Testing (CAT)
Caregiver distress will be assessed using Computer Adaptive Testing (CAT) administered electronically. Distress will be quantified using CAT-generated distress scores. Unit of Measure: CAT distress score (continuous scale)
Time frame: From enrollment to the end of the study at month 2
Psychosocial Patterns and Caregiver Responses to Glucose Events - Caregiver Distress (Parent Diabetes Distress Scale)
Caregiver distress will be measured using the Parent Diabetes Distress Scale (Parent-DDS), a 20-item questionnaire assessing four subscales: * Personal distress * Teen management distress * Parent/teen relationship distress * Healthcare team distress Scoring: For each scale and the total score, responses are summed and divided by the number of items in that scale, yielding a mean item score ranging from 0 to 5. Interpretation of scores: * -1.9: Little or no distress * 2.0-2.9: Moderate distress * ≥3.0: High distress Higher scores indicate greater caregiver distress. Associations between Parent-DDS scores (total and subscale scores) and children's severe glucose events (hyperglycemia \>250 mg/dL for \>2 hours or hypoglycemia \<70 mg/dL for \>15 minutes) will be analyzed. Clinicians may consider moderate or high distress worthy of clinical attention depending on context.
Time frame: From enrollment to the end of the study at month 2
Mobile Application Engagement
Engagement will be quantified using app logs and user profiling, including frequency and duration of interactions with the Adhera Caring Digital Program®.
Time frame: From enrollment to the end of study at month 2
Frequency of Severe Glucose Events in Children
Outcome Measure Description Severe glucose events will be defined as hyperglycemia \>250 mg/dL for more than 2 hours or hypoglycemia \<70 mg/dL for more than 15 minutes, as measured by continuous glucose monitoring. Unit of Measure Number of severe glucose events. Higher number, worse outcome
Time frame: From enrollment to the end of the study at month 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jan 2026, 2 months.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 2 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adhera Health, Inc.